New tumor profiling papers stemming from prior clinical trials led to informative mutations in early-stage, ER+/HER2- breast cancer and lung squamous cell carcinoma.
In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.
Unicancer will provide patients with centralized laboratory testing performed by Agendia, and also adopt the company's NGS kits for decentralized testing.
A new study suggests that enhanced tumor clone frequencies, found by T cell receptor beta gene sequencing, coincide with poorer mycosis fungoides outcomes.
Homologous recombination deficiency predicted with the HRDetect tool corresponded to favorable breast cancer outcomes after platinum-based chemotherapy.
New studies suggest low-, intermediate-, and high-methylation subgroups exist in juvenile myelomonocytic leukemia, potentially offering insights into patient outcomes.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
ASCO said MammaPrint should be used to inform decisions on withholding chemotherapy for these clinically high risk, HR-positive, HER2-negative breast cancers.
A small study of prostate cancers from African American and European American men uncovered ancestry-associated splicing with apparent ties to tumor aggressiveness and resistance.
Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.
